Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 13/20 | 0.36 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | ADAM8 | P78325 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799336 | 0.93 | F2 (0.34) | SLC9A3 | |
| SCHEMBL3874559 | 0.92 | NPY4R (0.36) | SLC9A3 | |
| SCHEMBL1800587 | 0.91 | SLC9A3 (0.33) | SLC9A3 | |
| SCHEMBL4293042 | 0.91 | LTA4H (0.33) | SLC9A3MMP2MMP9MMP12MMP14 | |
| SCHEMBL4372334 | 0.87 | LTA4H (0.40) | ADAM10MMP2MMP9MMP12MMP14 | |
| SCHEMBL1800732 | 0.85 | MAP2K1 (0.33) | — | |
| SCHEMBL4370906 | 0.82 | SCN9A (0.36) | — | |
| SCHEMBL4377327 | 0.82 | F2 (0.39) | MMP2MMP9MMP14 | |
| SCHEMBL4375795 | 0.81 | TBXA2R (0.34) | — | |
| SCHEMBL4371687 | 0.81 | SMN1; SMN2 (0.36) | MMP2MMP9MMP12MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | SLC9A3 753/4885ADAM10 1/4885MMP2 133/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | SLC9A3 377/4885ADAM10 1/4885MMP2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.